ASCO 2019 Conference Review - focus on GU, reviewed by Dr. Ben Tran

In this review:

Analysis of KEYNOTE-426 shows benefit with pembro/axi across all disease risks groups in mRCC
Pazopanib in mRCC postmetastasectomy
Switch maintenance with pembrolizumab in mUC
EV-201: enfortumab vedotin in heavily pre-treated mUC
Adjuvant chemotherapy vs adjuvant radiotherapy for locally advanced bladder cancer
Cytoreductive nephrectomy in mRCC
Active surveillance in mRCC
SAUL subgroup analysis shows more favourable OS with PD-L1 expression in mUC
Significantly improved outcomes in S/R mRCC tumours with immune checkpoint inhibition
Biomarker analyses from JAVELIN Renal 101

Please login below to download this issue (PDF)